Archives: Search / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
May 6, 2021 -Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter-
|
Apr 13, 2021 Topline TIDAL Study Data on Track to be Reported in the Fourth Quarter
|
Apr 10, 2021 Data Featured in Poster at American Association for Cancer Research Annual Meeting 2021
|
Feb 4, 2021 --Multiple Clinical Development Milestones Anticipated in 2021--
|
Jan 4, 2021 - Safety Review Committee approved Phase 1b expansion cohorts in study arm evaluating zandelisib in combination with zanubrutinib in various B-cell maligniancies -
|
Nov 10, 2020 --Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment--
|
Sep 9, 2020 - Strong cash position of ~$183 million at start of fiscal year 2021 -
|
